KRAS is confirmed to be the most frequently mutated oncogene in various tumors, notably in colorectal cancer, pancreatic ductal adenocarcinoma, etc. Oncogenic KRAS mutations contribute to tumor progression not only by driving proliferation but also by modulating the tumor microenvironment. Here, KRAS is linked to colorectal cancer.